Results 201 to 210 of about 1,988,593 (307)

Is there a best frontline therapy in chronic myeloid leukemia? [PDF]

Haematologica
Jain AG, Dalgetty M, Cortes JE.
europepmc   +1 more source

Molecular Glue Degraders in Early Development for Cancer Therapy

Medicinal Research Reviews, EarlyView.
ABSTRACT Molecular glue degraders are an emerging class of small molecule allosteric modulators that induce or stabilize protein‐protein interactions, enabling targeted degradation of previously intractable proteins. By redirecting E3 ligases to recognize neosubstrates, proteins that are not typically recognized by a specific E3 ubiquitin ligase, they ...
E. Sila Ozdemir, Hyunbum Jang, Ozlem Keskin, Attila Gursoy, Ruth Nussinov   +4 more
wiley   +1 more source

Mitochondrial DNA mutations are associated with impaired oxidative phosphorylation and enhanced imatinib response in chronic myeloid leukemia. [PDF]

Hemasphere
Pagani IS, Krishnan V, Ouyang JF, Kok CH, Chen B, Lee KL, Pham CM, Wang P, Page E, Dang P, Saunders VA, James J, Lim K, Mangiola S, Gao Y, Shanmuganathan N, Yong A, Branford S, Chuah C, Yeung DT, White DL, Helgason VG, Thomas D, Ong ST, Hughes TP, Ross DM.   +25 more
europepmc   +1 more source

Information Design for Early‐Stage Dose‐Finding Trials

Naval Research Logistics (NRL), EarlyView.
ABSTRACT To enhance enrollment rates in early‐stage dose‐finding clinical trials, we propose an information design approach, where the clinical investigator (CI) commits to an information releasing mechanism (IRM) based on the treatment's uncertain efficacy and toxicity to encourage patients to participate in the trial.
Amin Khademi, Ningyuan Chen
wiley   +1 more source

A Rare Case of Cutaneous Extramedullary Hematopoiesis in Chronic Myeloid Leukemia. [PDF]

J Cutan Pathol
Christie-Nguyen B, El Achi H, Iashvili L, Wahed A, Mai B, Armstrong J.   +5 more
europepmc   +1 more source

Ineffectiveness of immune checkpoint inhibitors in prostate cancer: is it just a question of ‘‐mabs’?

The Journal of Pathology, EarlyView.
Abstract Prostate cancer (PCa) is the second most common type of neoplasm, currently treated with a variety of therapeutic agents. Although advances in treatment over the past decade have improved overall survival, patients with advanced PCa eventually progress from hormone‐sensitive PCa to metastatic castration‐resistant PCa.
Giuseppe Schepisi, Irene Torresan, Emilio Francesco Giunta, Sara Bleve, Nicole Brighi, Elisa Tassinari, Sofia Zanuccoli, Maria Concetta Cursano, Cristian Lolli   +8 more
wiley   +1 more source

Effects of a High-Fat Meal on the Pharmacokinetics of Olverembatinib in Patients With Chronic Myeloid Leukemia. [PDF]

Clin Transl Sci
Wang H, Yang Y, Chen Z, Yu M, Jiang L, Men L, Yan H, Yang D, Zhai Y.   +8 more
europepmc   +1 more source

In Utero HSC Transplantation for Sickle Cell Disease: A Potential Therapeutic Approach That Overcomes Complications of Current Therapies

Prenatal Diagnosis, EarlyView.
ABSTRACT Sickle cell disease (SCD) affects millions worldwide but has limited treatment options, most of which carry significant side effects. At present, the only curative treatment for SCD is allogeneic or gene‐modified autologous hematopoietic stem cell (HSC) transplantation (Tx).
Oluwaseun O. Babatunde, Madeleine G. Bibby, Anthony Atala, Graça Almeida‐Porada, Christopher D. Porada   +4 more
wiley   +1 more source

Beta Thalassemia and Chronic Myeloid Leukemia: Dual Diagnosis Under the Microscope. [PDF]

Int J Lab Hematol
Muir P, Bahmanyar M, Nicolson H, Merkeley H.   +3 more
europepmc   +1 more source

Before Guillain‐Barre Syndrome Is Attributed to a CMV Infection, the Diagnosis Must Be Confirmed and Other Causes Must Be Ruled Out

The Kaohsiung Journal of Medical Sciences, EarlyView.
Josef Finsterer
wiley   +1 more source